Direct Bilirubin
Enzymatic Method, Bilirubin. 510(k) K152343, from Randox Laboratories Limited (Crumlin, GB). Product code JFM, class 2.
As of Nov 22, 2026, K152343 is an FDA 510(k) held by Randox Laboratories Limited, substantially equivalent on Feb 16, 2016 after 181 days, with no recalls tied to it in FDA's recall database.
- Review time: 181 days
- Recalls: 0
The Direct Bilirubin test system is a device intended for the quantitative in vitro determination of Direct Bilirubin in serum and plasma. Bilirubin measurements can be used in the diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders including hepatitis and gall bladder block. This device is for
- Wako Direct Bilirubin V, Models 996-23591, 412-22901, 992-23691, 998-23791K053132 · Wako Chemicals USA, Inc. · Dec 30, 2005
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Aug 19, 2015
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1110
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files